PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (...
November 15 2017 - 1:04AM
REGULATED INFORMATION
GHENT, Belgium, 15 November 2017 -
Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today
announced, in accordance with Article 14 of the Belgian Law of 2
May 2007 regarding the publication of major shareholdings in
issuers whose securities are admitted to trading on a regulated
market (the "Transparency Law"), that it received a notification of
shareholdings from Perceptive Advisors LLC on 13 November 2017.
Perceptive Advisors LLC notified Ablynx that it
holds 3,400,628 voting securities of Ablynx on 30 October 2017,
representing 4.55% of the 74,720,644 outstanding voting rights of
Ablynx, and thereby passively downward crossing the 5%
threshold.
The notification contains the following
information:
- Reason for the notification: passive crossing of a
threshold
- Notification by: a parent undertaking or a controlling
person
- Persons subject to the notification requirement:
Perceptive Advisors LLC - Joseph Edelman
- Date on which threshold is crossed: 30 October 2017
- Threshold that is crossed: 5%
- Denominator: 74,720,644
- Details of the notification: Perceptive Advisors LLC
holds 3,400,628 voting securities of Ablynx
- Chain of controlled undertakings through which the holding
is effectively being held: Joseph Edelman controls Perceptive
Advisors in accordance to article 3,§1, 5° of the Companies
Code
- Additional information: Perceptive Advisors LLC holds
3,150,628 ordinary shares (traded on Euronext Brussels) and 250,000
American Depository Shares (traded on Nasdaq) of Ablynx
More
information is provided in the transparency notification. Full
versions of the transparency notifications are available on Ablynx
website, under the section Investors.
The Articles of the Association of Ablynx NV
provide for shareholders notification threshold of 3%, 5% or a
multiple of 5% of the total number of existing voting rights.
About Ablynx
Ablynx is a biopharmaceutical company engaged in
the development of Nanobodies, proprietary therapeutic proteins
based on single-domain antibody fragments, which combine the
advantages of conventional antibody drugs with some of the features
of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the
Company has more than 45 proprietary and partnered programmes in
development in various therapeutic areas including inflammation,
haematology, immuno-oncology, oncology and respiratory disease. The
Company has collaborations with multiple pharmaceutical companies
including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck &
Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo
Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is
headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please
contactAblynx:Dr Edwin MosesCEOt: +32 (0)9
262 00 07m: +32 (0)473 39 50 68e: edwin.moses@ablynx.com
Lies VannesteDirector Investor Relationst: +32 (0)9
262 01 37m: +32 (0)498 05 35 79 e:
lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations:Consilium Strategic
CommunicationsMary-Jane Elliott, Philippa Gardner, Sukaina
Virjit: +44 (0)20 3709 5700e:
ablynx@consilium-comms.com
DisclaimerCertain statements, beliefs and
opinions in this press release are forward-looking, which reflect
the Company or, as appropriate, the Company directors' current
expectations and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, competition and technology, can
cause actual events, performance or results to differ significantly
from any anticipated development. Forward looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, the Company
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in
events, conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its parent or subsidiary
undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in
this press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/8a52f6cc-c5a9-4e53-9090-127d1cbf7fa0